About this trial
This study looks at a new treatment called CRD3874-SI for people with a type of cancer called acute myeloid leukemia (AML). The goal is to see if CRD3874-SI is safe for patients whose AML has come back or has not responded to other treatments. Researchers want to find out how well this treatment works for these patients.
The trial's ID number is NCT07661095. This is a Phase 1 study, which means it is the first step in testing how well CRD3874-SI works and how safe it is. The trial is FDA-regulated and aims to include 24 participants.
Who can join
Adults aged 18 and older can join. This study is open to men and women with relapsed or refractory acute myeloid leukemia. Participants must have specific health conditions and organ function. Those with certain other cancers or severe complications from leukemia cannot join. The trial team will check to see who is eligible.
Conditions
Acute Myeloid Leukemia, AML, Refractory Acute Myeloid Leukemia
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will receive one of three doses of CRD3874-SI through a treatment plan. This is done randomly, meaning some will get different doses. Everyone will be monitored closely to see how well they tolerate the treatment and if it is effective.
Where
This trial is running at 7 locations in the United States. All of them are currently recruiting.
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey
Memorial Sloan Kettering Nassau (All Protocol Activities)
Rockville Centre, New York
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
Commack, New York
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, New York